ハナフサ　ノリオ   HANAFUSA, Norio   花房　規男    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	総説
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	CART: Cell-free and Concentrated Ascites Reinfusion Therapy against malignancy-related ascites.
掲載誌名	正式名：Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 略　 称：Transfus Apher Sci ISSNコード：(1473-0502)1473-0502(Linking)
掲載区分	国外
巻・号・頁	56(5),pp.703-707
著者・共著者	Ito Tetsuya, Hanafusa Norio
担当区分	最終著者
発行年月	2017/10
概要	A standard strategy against ascites, a common symptom observed in cirrhotic and cancer patients, includes restriction of sodium intake and use of a diuretic. Paracentesis is a widely applied method against refractory ascites that do not react to such treatment. However, emerging fatigue and hemodynamic instability are possibly attributable to a loss of protein included in ascites. Cell-free and Concentrated Ascites Reinfusion Therapy (CART) is also applied against refractory ascites. CART comprises three processes. After ascites is first filtered to remove cell components, it is concentrated to reduce its volume. Fluid obtained through these processes, including useful proteins such as albumin and globulin, is finally reinfused intravenously. CART was reported first in the 1970s. Since then, it has been applied mainly against cirrhotic ascites with a thinner cell component. Now, its indication is expanding to include malignancy-related ascites. Additionally, CART can be applied safely against malignancy-related ascites. Its favorable effects on control of patients' symptoms are anticipated, especially on fatigue. Although related evidence has not been established, CART can be anticipated for use as a strategy against refractory ascites.
DOI	10.1016/j.transci.2017.08.018
PMID	28916401